<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35726132</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>8</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review.</ArticleTitle><Pagination><StartPage>1391</StartPage><EndPage>1399</EndPage><MedlinePgn>1391-1399</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03007995.2022.2081454</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We conducted literature reviews to uncover differential effects of sex on sequelae from coronavirus disease 2019 (COVID-19) and on long COVID syndrome.</AbstractText><AbstractText Label="METHODS">Two authors independently searched OvidSP in Embase, Medline, Biosis, and Derwent Drug File. Publications reporting original, sex-disaggregated data for sequelae of COVID-19 (published before August 2020) and long COVID syndrome (published before June 2021) were included in the reviews. The association between COVID-19 sequelae (i.e. lasting &lt;4&#x2009;weeks after symptom onset) and sex, and between long COVID syndrome (i.e. lasting &gt;4&#x2009;weeks after symptom onset) and sex, was determined by odds ratio (OR) and 95% confidence interval (CI) (statistical significance defined by 95% CI not including 1).</AbstractText><AbstractText Label="RESULTS">Of 4346 publications identified, 23 and 12 met eligibility criteria for COVID-19 sequelae and long COVID syndrome, respectively. COVID-19 sequelae in the categories of psychiatric/mood (OR&#xa0;=&#xa0;1.80; 95% CI:&#xa0;1.35-2.41), ENT (OR&#xa0;=&#xa0;1.42; 95% CI:&#xa0;1.39-1.46), musculoskeletal (OR&#xa0;=&#xa0;1.15; 95% CI:&#xa0;1.14-1.16), and&#xa0;respiratory (OR&#xa0;=&#xa0;1.09; 95% CI:&#xa0;1.08-1.11) were significantly more likely among females (vs. males), whereas renal sequelae (OR&#xa0;=&#xa0;0.83; 95% CI:&#xa0;0.75-0.93) were significantly more likely among males. The likelihood of having long COVID syndrome was significantly greater among females (OR&#xa0;=&#xa0;1.22; 95% CI:&#xa0;1.13-1.32), with the odds of ENT (OR&#xa0;=&#xa0;2.28; 95% CI:&#xa0;1.94-2.67), GI (OR&#xa0;=&#xa0;1.60; 95% CI:&#xa0;1.04-2.44), psychiatric/mood (OR&#xa0;=&#xa0;1.58; 95% CI:&#xa0;1.37-1.82), neurological (OR&#xa0;=&#xa0;1.30; 95% CI:&#xa0;1.03-1.63), dermatological (OR&#xa0;=&#xa0;1.29; 95% CI:&#xa0;1.05-1.58), and other (OR&#xa0;=&#xa0;1.36; 95% CI:&#xa0;1.25-1.49) disorders significantly higher among females and the odds of endocrine (OR&#xa0;=&#xa0;0.75; 95% CI:&#xa0;0.69-0.81) and renal disorders (OR&#xa0;=&#xa0;0.74; 95% CI:&#xa0;0.64-0.86) significantly higher among males.</AbstractText><AbstractText Label="CONCLUSIONS">Sex-disaggregated differences for COVID-19 sequelae and long COVID syndrome were observed. Few COVID-19 studies report sex-disaggregated data, underscoring the need for further sex-based research/reporting of COVID-19 disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sylvester</LastName><ForeName>Shirley V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Women's Health, Office of the Chief Medical Officer, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusu</LastName><ForeName>Rada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Operations, Johnson &amp; Johnson, Office of the Chief Medical Officer, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Biankha</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Operations, Johnson &amp; Johnson, Office of the Chief Medical Officer, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellows</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Healthcare Technology Center, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Carly</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Healthcare Technology Center, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Women's Health, Office of the Chief Medical Officer, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">female</Keyword><Keyword MajorTopicYN="N">long COVID syndrome</Keyword><Keyword MajorTopicYN="N">sex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>0</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35726132</ArticleId><ArticleId IdType="doi">10.1080/03007995.2022.2081454</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>